중등도-중증 궤양성 대장염 환자에서 infliximab의 치료효과에 대한 메타분석

키워드

참고문헌 (52)

1. Lakatos PL, "Recent trends in the epidemiology of inflammatory bowel diseases: up or down?", World J Gastroenterol, 12, pp.6102~6108 (2006)
2. Kornbluth A, "Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee", Am J Gastroenterol, 99, pp.1371~1385 (2004)
3. Willert RP, "Use of infliximab in the prevention and delay of colectomy in severe steroid dependent and refractory ulcerative colitis", World J Gastroenterol, 14, pp.2544~2549 (2008)
4. Järnerot G, "Intensive intravenous treatment of ulcerative colitis", Gastroenterology, 89, pp.1005~1013 (1985)
5. Lichtiger S, "Cyclosporine in severe ulcerative colitis refractory to steroid therapy", N Engl J Med, 330, pp.1841~1851 (1994)
6. Laharie D, "Cyclosporin versus infliximab in severe acute ulcerative colitis refractory to intravenous steroids: A randomized trial. Gastroenterology", Conference: Digestive Disease Week, DDW 2011, 140(5 SUPPL. 1), pp.S112~ (2011)
7. Arts J, "Long-term outcome of treatment with intravenous cyclosporine in patients with severe ulcerative colitis", Inflamm Bowel Dis, 10, pp.73~78 (2004)
8. Pham CQ, "Cyclosporine for severe ulcerative colitis", Ann Pharmacother, 40, pp.96~101 (2006)
9. Van AG, "Treatment of severe steroid refractory ulcerative colitis", World J Gastroenterol, 14, pp.5508~5511 (2008)
10. 김승희, "조혈모세포이식을 받은 한국 성인 백혈병환자에서 cyclosporine의 집단약동학 분석", 한국임상약학회지, 20(1), pp.9~16 (2010), 한국임상약학회
11. Shibolet O, "Cyclosporine A for induction of remission in severe ulcerative colitis", Cochrane Database Syst Rev, pp.CD004277~ (2005)
12. Penna C, "Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis", Gut, 38, pp.234~239 (1996)
13. McIntyre PB, "Comparing functional results one year and ten years after ileal pouchanal anastomosis for chronic ulcerative colitis", Dis Colon Rectum, 37, pp.303~307 (1994)
14. Hahnloser D, "The effect of aging on function and quality of life in ileal pouch patients: a single cohort experience of 409 patients with chronic ulcerative colitis", Ann Surg, 240, pp.615~621 (2004)
15. Ording OK, "Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample", Gastroenterology, 122, pp.15~19 (2002)
16. 김경옥, "염증성장질환의 치료: 새로운 약제를 중심으로", 대한소화기학회지, 58(5), pp.235~244 (2011), 대한소화기학회
17. Papadakis KA, "Tumor necrosis factor: biology and therapeutic inhibitors", Gastroenterology, 119, pp.1148~1157 (2000)
18. Hove T, "Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease", Gut, 50, pp.206~211 (2002)
19. Rutgeerts P, "Optimizing anti-TNF treatment in inflammatory bowel disease", Gastroenterology, 126, pp.1593~1610 (2004)
20. Travassos WJ, "Infliximab: Use in Inflammatory Bowel Disease", Curr Treat Options Gastroenterol, 8, pp.187~196 (2005)
21. Regueiro M, "Infliximab for hospitalized patients with severe ulcerative colitis", J Clin Gastroenterol, 40, pp.476~481 (2006)
22. Yamamoto-Furusho JK, "Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids", Dig Surg, 25, pp.383~386 (2008)
23. Talley NJ, "An evidence-based systematic review on medical therapies for inflammatory bowel disease", Am J Gastroenterol, 106, pp.S2~S25 (2011)
24. Jadad AR, "Assessing the quality of reports of randomized clinical trials: is bliniding necessary?", Control Clin Trials, 17, pp.1~12 (1996)
25. Clark HD, "Assessing the quality of randomized trials: reliability of the Jadad scale", Control Clin Trials, 20, pp.448~452 (1999)
26. Cochran WG, "The combination of estimates from different experiments", Biometrics, 10, pp.101~129 (1954)
27. Gustavsson A, "Clinical trial: colectomy after rescue therapy in ulcerative colitis 3-year follow-up of the Swedish-Danish controlled infliximab study", Aliment Pharmacol Ther, 32, pp.984~989 (2010)
28. Sandborn WJ, "Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab", Gastroenterology, 137, pp.1250~1260 (2009)
29. Feagan BG, "The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients", Am J Gastroenterol, 102, pp.794~802 (2007)
30. Gavalas E, "Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients", Hepatogastroenterology, 54, pp.1074~1079 (2007)
31. Jarnerot G, "Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study", Gastroenterology, 128, pp.1805~1811 (2005)
32. Rutgeerts P, "Infliximab for induction and maintenance therapy for ulcerative colitis", N Engl J Med, 353, pp.2462~2476 (2005)
33. Armuzzi A, "Infliximab in the treatment of steroid-dependent ulcerative colitis", Eur Rev Med Pharmacol Sci, 8, pp.231~233 (2004)
34. Ochsenkühn T, "Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study", Eur J Gastroenterol Hepatol, 16, pp.1167~1171 (2004)
35. Probert CJ, "Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial", Gut, 52, pp.998~1002 (2003)
36. Sands BE, "Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study", Infl amm Bowel Dis, 7, pp.83~88 (2001)
37. Irvine EJ, "A quality-of-life index for inflammatory bowel disease", Can J Gastroenterol, 7, pp.155~159 (1993)
38. Egger M, "Meta-analysis: potentials and premise", BMJ, 315, pp.1371~1374 (1997)
39. 최윤영, "제 2형 당뇨 환자에서 자가혈당측정의 임상적 유용성 : 체계적문헌고찰 및 메타분석", 한국임상약학회지, 20(3), pp.183~192 (2010), 한국임상약학회
40. Ford AC, "Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis", Am J Gastroenterol, 106, pp.644~659 (2011)
41. Huang X, "A meta-analysis of the therapeutic effects of tumor necrosis factor-α blockers on ulcerative colitis", Eur J Clin Pharmacol, 67, pp.759~766 (2011)
42. Samsa G, "Determining clinically important differences in health status measures: a general approach with illustration to the health utilities index mark II", Pharmacoeconomics, 15, pp.141~155 (1999)
43. Hjortswang H, "The Short Health Scale: a valid measure of subjective health in ulcerative colitis", Scand J Gastroenterol, 41, pp.1196~1203 (2006)
44. Sullivan M, "The Swedish SF-36 Health Survey – I. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden", Soc Sci Med, 41, pp.1349~1358 (1995)
45. Taft C, "Performance of the Swedish SF-36 version 2.0", Qual Life Res, 13, pp.251~256 (2004)
46. Irvine EJ, "Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group", Gastroenterology, 106, pp.287~296 (1994)
47. Walmsley RS, "A simple clinical colitis activity index", Gut, 43, pp.29~32 (1998)
48. Seo M, "Correlation between endoscopic severity and the clinical activity in ulcerative colitis", Am J Gastroenterol, 93, pp.2124~2129 (1998)
49. Higgins PD, "Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?", Am J Gastroenterol, 100, pp.355~361 (2005)
50. Williams A, "EuroQol-a new facility for the measurement of health-related quality of life", Health Policy, 16, pp.199~208 (1990)
51. Gurwitz JH, "Glucocorticoids and the risk for initiation of hypoglycemic therapy", Arch Intern Med, 154, pp.97~101 (1994)
52. Clowes JA, "Glucocorticoid-induced osteoporosis", Curr Opin Rheumatol, 13, pp.326~332 (2001)

관련 논문AI추천